These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 1425598)

  • 1. Cell death in Parkinson's disease.
    Greenfield SA
    Essays Biochem; 1992; 27():103-18. PubMed ID: 1425598
    [No Abstract]   [Full Text] [Related]  

  • 2. What process causes nigral cell death in Parkinson's disease?
    Jenner P
    Neurol Clin; 1992 May; 10(2):387-403. PubMed ID: 1584181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A channel to neurodegeneration.
    Deutch AY; Winder DG
    Nat Med; 2006 Jan; 12(1):17-8. PubMed ID: 16397545
    [No Abstract]   [Full Text] [Related]  

  • 4. Oxidative mechanisms in nigral cell death in Parkinson's disease.
    Jenner P
    Mov Disord; 1998; 13 Suppl 1():24-34. PubMed ID: 9613715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Parkinsonism induced by MPTP as an experimental model of Parkinson disease: similarities and differences].
    Luquin MR; Obeso JA; Herrero MT; Laguna J; Martínez-Lage JM
    Neurologia; 1991 Oct; 6(8):287-94. PubMed ID: 1790005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of adenosine triphosphate-sensitive potassium channels confers protection against rotenone-induced cell death: therapeutic implications for Parkinson's disease.
    Tai KK; Truong DD
    J Neurosci Res; 2002 Aug; 69(4):559-66. PubMed ID: 12210849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The origin of Parkinson's disease].
    Rinne J
    Duodecim; 1997; 113(18):1819-24. PubMed ID: 10892075
    [No Abstract]   [Full Text] [Related]  

  • 9. Mechanisms of MPTP toxicity.
    Przedborski S; Jackson-Lewis V
    Mov Disord; 1998; 13 Suppl 1():35-8. PubMed ID: 9613716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease.
    Anglade P; Vyas S; Javoy-Agid F; Herrero MT; Michel PP; Marquez J; Mouatt-Prigent A; Ruberg M; Hirsch EC; Agid Y
    Histol Histopathol; 1997 Jan; 12(1):25-31. PubMed ID: 9046040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogenesis of nigral cell death in Parkinson's disease.
    Przedborski S
    Parkinsonism Relat Disord; 2005 Jun; 11 Suppl 1():S3-7. PubMed ID: 15885625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of Parkinson's disease-associated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP.
    Dong Z; Ferger B; Feldon J; Büeler H
    J Neurobiol; 2002 Oct; 53(1):1-10. PubMed ID: 12360578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iron and ferritin in substantia nigra in Parkinson's disease.
    Jellinger KA; Kienzl E; Rumpelmaier G; Paulus W; Riederer P; Stachelberger H; Youdim MB; Ben-Shachar D
    Adv Neurol; 1993; 60():267-72. PubMed ID: 8420142
    [No Abstract]   [Full Text] [Related]  

  • 14. Membrane-permeable Bcl-xL prevents MPTP-induced dopaminergic neuronal loss in the substantia nigra.
    Dietz GP; Stockhausen KV; Dietz B; Falkenburger BH; Valbuena P; Opazo F; Lingor P; Meuer K; Weishaupt JH; Schulz JB; Bähr M
    J Neurochem; 2008 Feb; 104(3):757-65. PubMed ID: 17995935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine-induced, genotoxic activation of programmed cell death. A role in nigrostriatal neuronal degeneration in Parkinson's disease?
    Ziv I; Barzilai A; Offen D; Stein R; Achiron A; Melamed E
    Adv Neurol; 1996; 69():229-33. PubMed ID: 8615132
    [No Abstract]   [Full Text] [Related]  

  • 17. Microglial activation is not prevented by tacrolimus but dopamine neuron damage is reduced in a rat model of Parkinson's disease progression.
    Wright AK; Miller C; Williams M; Arbuthnott G
    Brain Res; 2008 Jun; 1216():78-86. PubMed ID: 18495090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of MPTP toxicity and their implications for therapy of Parkinson's disease.
    Watanabe Y; Himeda T; Araki T
    Med Sci Monit; 2005 Jan; 11(1):RA17-23. PubMed ID: 15614202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
    Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
    J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurofilament mRNA is reduced in Parkinson's disease substantia nigra pars compacta neurons.
    Hill WD; Arai M; Cohen JA; Trojanowski JQ
    J Comp Neurol; 1993 Mar; 329(3):328-36. PubMed ID: 8459049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.